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PSirolimus-Induced Vascular Dysfunction
Increased Mitochondrial and Nicotinamide
Adenosine Dinucleotide Phosphate Oxidase-Dependent
Superoxide Production and Decreased Vascular Nitric Oxide Formation
Alexander Jabs, MD, Sebastian Göbel, MS, Philip Wenzel, MD, Andrei L. Kleschyov, PHD,
Marcus Hortmann, MS, Matthias Oelze, PHD, Andreas Daiber, PHD, Thomas Münzel, MD
Mainz, Germany
Objectives This study sought to analyze mechanisms that mediate vascular dysfunction induced by sirolimus.
Background Despite excellent antirestenotic capacity, sirolimus-eluting stents have been found to trigger coronary endothe-
lial dysfunction and impaired re-endothelialization.
Methods To mimic the continuous sirolimus exposure of a stented vessel, Wistar rats underwent drug infusion with an
osmotic pump for 7 days.
Results Sirolimus treatment caused a marked degree of endothelial dysfunction as well as a desensitization of the vascula-
ture to the endothelium-independent vasodilator nitroglycerin. Also, sirolimus stimulated intense transmural superox-
ide formation as detected by dihydroethidine fluorescence in aortae. Increased superoxide production was mediated
in part by the vascular nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase as indicated by a marked
stimulation of p67phox/rac1 NADPH oxidase subunit expression and by increased rac1 membrane association. In ad-
dition, superoxide production in rat heart mitochondria was up-regulated by sirolimus, as measured by L012-
enhanced chemiluminescence. As a consequence, electron spin resonance measurements showed a 40% reduction
in vascular nitric oxide bioavailability, which was further supported by decreased serum nitrite levels.
Conclusions Sirolimus causes marked vascular dysfunction and nitrate resistance after continuous treatment for 7 days. This
impaired vasorelaxation may, in part, be induced by up-regulated mitochondrial superoxide release as well as by
an up-regulation of NADPH oxidase-driven superoxide production. Both processes could contribute to endothelial
dysfunction observed after coronary vascular interventions with sirolimus-coated stents. (J Am Coll Cardiol
2008;51:2130–8) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.058m
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dndothelial dysfunction and oxidative stress play an essen-
ial role in the progression of atherosclerosis and predict the
isk of cardiovascular events in patients with coronary heart
isease (CHD) (1). Coronary stent implantation has be-
ome a standard treatment modality for patients with
ymptomatic CHD, and drug-eluting stents (DES) have
urther improved angiographic and clinical outcomes (2,3).
espite excellent antirestenotic capacity, sirolimus-eluting
tents can trigger coronary endothelial dysfunction, impair-
ent of coronary collateral function, late stent thrombosis,
nd delayed re-endothelialization in some patients (4–9).
rom the II Medizinische Klinik für Kardiologie und Angiologie, Johannes Guten-
erg University, Mainz, Germany. Supported by a vascular biology grant from Cordis
mbH, Langenfeld, Germany (Drs. Jabs and Münzel), a research grant from the
ohannes Gutenberg University (Drs. Daiber, Hortmann, and Wenzel), the Deutsche
tiftung für Herzforschung, Frankfurt/M., Germany (Drs. Wenzel and Münzel), and
he Deutsche Forschungsgemeinschaft, Bonn, Germany (SFB 553-C17, Drs. Daiber
nd Münzel).t
Manuscript received October 11, 2007; revised manuscript received December 31,
007, accepted January 21, 2008.Although local drug-related effects are very likely to
odulate coronary vascular function, little is known about
otential influences of sirolimus on the endothelium. Siroli-
us (rapamycin) induces smooth muscle and endothelial
ell cycle arrest in the late G1 phase by forming a complex
ith FK506-binding protein 12 (FKBP12) that inhibits the
rotein Ser-Thr kinase mammalian target of rapamycin
See page 2139
mTOR), with mTOR being a central element in signaling
athways involved in the control of cell growth and prolif-
ration (10–12). Recently, Long et al. (13,14) showed that
cute in vitro sirolimus treatment as well as genetic deletion
f the sirolimus-receptor isoform FKBP12.6 increased pro-
ein kinase C (PKC)–mediated endothelial nitric oxide
ynthase (eNOS) threonine 495 phosphorylation, leading to
ecreased vascular nitric oxide (NO) production and endo-
helial dysfunction. However, the effects of a continuous
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June 3, 2008:2130–8 Sirolimus-Induced Vascular Dysfunctionn vivo sirolimus exposure as in a stented vessel (15) on vascular
unction have not been characterized in detail. Also, the role
nd sources of oxidative stress in sirolimus-induced vascular
ysfunction are not completely understood.
Therefore, in the present study, we established an animal
odel of vascular dysfunction induced by chronic sirolimus
reatment. We found increased reactive oxygen species
ROS) production, and hypothesized that this could contribute
o sirolimus-induced vascular dysfunction. We further assessed
he transmural distribution of vascular ROS formation, as well
s the cellular pathways that could lead to increased superoxide
roduction. Both nicotinamide adenosine dinucleotide phos-
hate (NADPH) oxidase and mitochondria were found to
ontribute significantly to the vascular superoxide load after
irolimus treatment.
ethods
nimal Studies
ale Wistar rats (n  34 in total, 300 to 330 g; Charles
iver, Sulzfeld, Germany) were anesthetized by isoflurane,
nd a subcutaneous osmotic minipump (model 1003D,
urect Corp., Cupertino, California) containing either
irolimus (sirolimus group) or the vehicle alone (dimethyl
ulfoxide, control group) was implanted. A continuous
irolimus infusion rate of 5 mg/kg/day was used because
ntiproliferative and immunomodulating effects of sirolimus
ave been described in the rat neointima model at a dosage
etween 1.5 and 6 mg/kg/day (16). Systemic levels of
irolimus were measured by high-performance liquid chro-
atography in whole-blood ethylene diamine tetra-acetic
cid samples by the local university clinic core laboratory.
irolimus concentration in rat blood was 14.2  5.7 g/l
t the time that the animals were euthanized. After 7
ays, animals were euthanized under isoflurane anesthe-
ia. Aortae and hearts were carefully removed and pro-
essed as described later in the text. All animal investi-
ations conformed to the Guide for the Care and Use of
aboratory Animals as adopted by the U.S. National
nstitutes of Health. Sirolimus was kindly provided by
yeth Pharma (Münster, Germany). All other chemicals
ere purchased from Sigma-Aldrich (St. Louis, Mis-
ouri), Merck (Darmstadt, Germany), or Fluka (Buchs,
witzerland).
ascular Reactivity Studies
asodilator responses to the endothelium-dependent vaso-
ilator acetylcholine (ACh) and the endothelium-
ndependent vasodilator nitroglycerin (NTG) were deter-
ined in organ chambers by isometric tension studies, as
escribed (17).
nalysis of NO Formation by Spin
rapping as NO-Fe(DETC)2 Complex
ascular NO formation was detected in rat aortic segments (3
m) using electron paramagnetic resonance as described (18). triefly, after an equilibration
eriod, medium was supple-
ented with 1 mol/l ACh plus
00 mol/l colloid Fe(II)-
iethyldithiocarbamate (Fe-
DETC]2) and further incubated
or 1 h. Vascular rings were then
rozen in liquid nitrogen and spec-
ra of electron paramagnetic reso-
ance were recorded at 77 K using
n X-band radiospectrometer
S200 (Magnettech, Berlin, Ger-
any). In control experiments, ad-
ition of the inhibitor of NO syn-
hase, NG-nitro-L-arginine
ethyl ester (L-NAME; 1 mmol/
), completely prevented the for-
ation of NO-Fe(DETC)2 in
ortae.
etection of NO Synthesis as
erum Nitrite
itrite, the oxidation product of
O, was analyzed in rat serum
y ozone chemiluminescence af-
er chemical reduction to NO as
measure of NO synthesis be-
ause nitrite levels correlate with
O biosynthesis (19).
nalysis of Vascular Superoxide
roduction
xidative fluorescent microto-
ography. The fluorescent dye dihydroethidine (DHE)
as used to detect superoxide in situ (20). To assess the
nfluence of eNOS-derived superoxide, vessels were incu-
ated with L-NAME (1 mM) as described (18,20). Also, in
ome experiments, aortic cross-sections were pre-incubated
ith the NADPH oxidase inhibitor apocynin (1 mM) (21).
horbol myristate (PMA)–induced ROS production.
horbol myristate–stimulated vascular ROS production was
easured using the chemiluminescence indicator reagent
iogenes, a luminol-peroxidase based assay (50% of total
eaction volume; National Diagnostics, Atlanta, Georgia)
22). Briefly, aortae were isolated in chilled buffer, cut into
-mm segments, and incubated for 30 min at 37°C in
anks buffered salt solution (PAA Laboratories, Pasching,
ustria). Then, a mixture of Diogenes containing dimeth-
lsulfoxide (0.1%, vehicle for PMA) and PMA (final con-
entration 100 nM; Calbiochem, San Diego, California)
as added. Chemiluminescence was quantified using a
ithras Microplate Luminometer (Berthold, Bad Wildbad,
ermany). Ten-second readings were obtained for each
ing over 60 min, and photon counts were normalized for
Abbreviations
and Acronyms
ACh  acetylcholine
CHD  coronary heart
disease
DES  drug-eluting stent(s)
DHE  dihydroethidine
eNOS  endothelial nitric
oxide synthase
FKBP12  FK506 binding
protein 12
L-NAME  NG-nitro-L-
arginine methyl ester
mPTP  mitochondrial
permeability transition pore
mTOR  mammalian target
of rapamycin
NADPH  nicotinamide
adenosine dinucleotide
phosphate
NO  nitric oxide
NOS  nitric oxide
synthase
NTG  nitroglycerin
PKC  protein kinase C
PMA  phorbol myristate
qRT-PCR  real-time
quantitative reverse-
transcriptase polymerase
chain reaction
ROS  reactive oxygen
specieshe dry weight of aortic tissue.
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Sirolimus-Induced Vascular Dysfunction June 3, 2008:2130–8eal-Time Quantitative Reverse-Transcriptase
olymerase Chain Reaction (qRT-PCR)
he messenger ribonucleic acid (mRNA) expression was
nalyzed with qRT-PCR as previously described (19). Briefly,
otal ribonucleic acid from rat aorta was isolated (RNeasy
ibrous Tissue Mini Kit, Qiagen, Hilden, Germany), and 0.5
g of total ribonucleic acid was used for RT-PCR analysis
ith the QuantiTect Probe RT-PCR kit (Qiagen). TATA
ox binding protein (TBP), eNOS, and Nox1 were obtained
rom MWG-Biotech (Ebersberg, Germany). A TaqMan
ene Expression assay Nox2/gp91phox was purchased as
robe-and-primer set (Applied Biosystems, Foster City, Cal-
fornia). Sequences of the primers and TaqMan probes were
forward, reverse, and probe) CTTCGTGCCAGAAAT-
CTGAA, TGTTCGTGGCTCTCTTATTCTCATG,
nd AATCCCAAGCGGTTTGCTGCAGTCA for TBP;
AGCAGCACAAGAGTTACAAAATCC, TCCAC-
GCTCGAGCAAAG, and CCACTGGTATCCTCTT-
GCGGCG for eNOS; and ACCCCCTGAGTCTTG-
AAGTG, GGGTGCATGACAACCTTGGT, and
GGATCCTTCGCTTTTATCGCTCCCG for Nox1.
he comparative Ct method was used for relative mRNA
uantification; gene expression was normalized to the endog-
nous control, TBP mRNA; and the amount of target gene
RNA in each sample was expressed relative to that of control.
etection of Superoxide Formation
n Isolated Rat Heart Mitochondria
itochondria were prepared from sirolimus-treated and
ontrol rats as described (23). Mitochondrial suspensions
ere diluted to a final protein concentration of 0.1 mg/ml in
.5 ml of phosphate-buffered saline containing the chemi-
uminescence dye 8-amino-5-chloro-7-phenylpyridol[3,
-d]pyridozine-1,2-(2H,3H) dione (L012; 100M), and
OS production was measured after stimulation with suc-
inate (4 mM final concentration) or malate/glutamate (2.5
M), respectively, as described (23). In a separate series of
xperiments, mitochondria were treated with cyclosporine
(0.2 M), glibenclamide (10 M), diazoxide (100 M),
otenone (5 M), antimycin A (20 g/ml) or myxothiazole
20 M) before the superoxide measurements (23,24).
xpression and Membrane
ssociation of Protein by Western Blotting
ample preparation and Western blotting was performed as
escribed (19,25). Incubations were performed with a
ouse monoclonal antibody against eNOS (dilution
:1,000), p67phox (dilution 1:500), rac1 (dilution 1:1000),
ox2 (dilution 1:500) (Transduction Laboratories, Rock-
ord, Illinois), goat polyclonal antibody Nox1 (dilution
:100; Santa Cruz Biotechnologies, Santa Cruz, California),
nd rabbit polyclonal p47phox (dilution 1:500, Upstate/
illipore, Billerica, Massachusetts). To determine mem-
rane association of p67phox, p47phox, and rac1, protein somogenates were divided into cytosolic and membrane
ractions by ultracentrifugation (1 h, 100,000g, 4°C).
tatistical Analysis
esults are expressed as mean  SEM. The half maximal
ffective concentration values were obtained by logit trans-
ormation. Statistically significant differences were deter-
ined using an unpaired 2-sample Student t test (SPSS
.0.1 for Windows, SPSS Inc., Chicago, Illinois). Values of
 0.05 were considered significant.
esults
ffects of Continuous Sirolimus Treatment
n Vascular Function and NO Bioavailability
irolimus caused endothelial dysfunction as indicated by
markedly reduced vasodilator response of intact rat
ortae to the endothelium-dependent vasodilator ACh
Fig. 1A, Table 1). Also, vascular relaxation to the
ndothelium-independent vasodilator nitroglycerin was im-
aired (Fig. 1B, Table 1). A significant reduction of NO
ormation as measured by electron paramagnetic resonance
as observed in aortic segments from sirolimus-treated rats
Fig. 1C). Accordingly, serum nitrite was significantly lower
n the sirolimus group (Fig. 1D).
ffects of Sirolimus on Vascular ROS Generation
ihydroethidine staining revealed a strong increase in
uperoxide throughout all vascular wall layers in aortae from
irolimus-treated animals (Figs. 2A and 2B). Pre-
ncubation with the eNOS inhibitor L-NAME specifically
ncreased DHE signaling in the endothelial monolayer of
ontrol animals (Fig. 2C), whereas neither transmural DHE
uorescence pattern nor intensity was changed in aorta of
irolimus-treated rats (Fig. 2D). In contrast, incubation
f aortic segments with the NADPH oxidase inhibitor
pocynin reduced vascular DHE fluorescence in the sirolimus
roup, albeit not to control levels (Figs. 2E and 2F).
uantitatively, vascular ROS formation in response to
ctivation of protein kinase C with PMA was substan-
ially increased in aortic segments of sirolimus-treated
nimals (Fig. 3).
ffects of Sirolimus on the Membrane
ssociation of NADPH Oxidase Subunits
irolimus up-regulated the expression of the NADPH
xidase subunits p67phox and rac1 in aortic segments (Table 2).
pecifically rac1 was found increased in the membrane
raction, that is, in its active membrane-associated form,
hereas p67phox and p47phox showed only nonsignificant
ncreases in membrane association (Fig. 4, Table 2). No
ignificant differences were found in the protein expression
f the NADPH oxidase isoforms NOX1 and NOX2,
lthough NOX1 mRNA seemed to be up-regulated in
irolimus-treated animals (Table 3). For eNOS, neither
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June 3, 2008:2130–8 Sirolimus-Induced Vascular DysfunctionRNA nor protein expression showed any changes induced
y sirolimus (Table 3).
ffects of Sirolimus on Mitochondrial ROS Formation
itochondrial ROS formation was measured using L012-
erived chemiluminescence. A significant increase in mito-
hondrial ROS was observed in the sirolimus group (Fig. 5A).
o analyze the underlying intracellular mechanisms contrib-
ting to increased mitochondrial ROS formation, we stud-
ed the effects of several modulators of mitochondrial
unction on ROS generation in separate series of experi-
ents: pre-incubation with either cyclosporine A, gliben-
lamide, or rotenone reduced mitochondrial ROS formation
fter sirolimus treatment (Fig. 5B). In contrast, incubation
ith diazoxide did not change ROS generation in mito-
hondria from sirolimus-treated animals, but triggered a
trong increase in the control group to levels similar to those
Figure 1 Effects of Sirolimus on Vascular Function, NO Formati
Effects of continuous sirolimus (Sir) infusion (5 mg/kg/day for 7 days) on the con
in aortic rings. (C) Electron paramagnetic resonance showing an approximately 40
7 rats per group). (D) Decreased serum nitrite levels (48%; †p  0.018; n  5
experiments. Ctr  control animals.
ffects of Sirolimus on Vascular Reactivity
Table 1 Effects of Sirolimus on Vascular Reactivity
In Vivo
Treatment
Potency,
EC50 (logM)
Efficacy,
Maximal Relaxation (%)
ACh NTG ACh NTG
Control, n 6 7.92 0.19 7.66 0.10 96.3 1.4 99.6 0.4
Sirolimus, n 9 7.44 0.23* 7.22 0.08† 86.4 4.5 96.2 1.6
asodilator potency of ACh and NTG in vessels from rats treated with vehicle (DMSO) or sirolimus
5mg/kg/d) for 7 days. Data are the mean SEM of n 5 independent experiments. *p 0.034.
p  0.009.m
ACh acetylcholine; DMSO dimethyl sulfoxide; EC50 half maximal effective concentration;
TG  nitroglycerin.bserved in the sirolimus group (Fig. 5B). Also, the respi-
atory chain inhibitors Antimycin A and myxothiazol in-
uced a 15- to 20-fold increase in mitochondrial ROS
ormation in both control and sirolimus groups (not shown).
hese findings were consistent for stimulation with the
omplex II substrate succinate (5 mM) (Fig. 5B) and the
omplex I substrates malate/glutamate (2.5 mM, not
hown).
iscussion
he results of the present study show that continuous sirolimus
reatment causes impaired endothelium-dependent and
independent vascular relaxation, reduced vascular NO bio-
vailability, and increased vascular ROS formation. This in-
rease is triggered in part by the vascular NADPH oxidase and
y increased mitochondrial ROS release. Our findings may
rovide new insights into the mechanisms that link sirolimus
harmacotherapy to vascular dysfunction, specifically in view of
ecent clinical data showing impaired coronary endothelial
unction after sirolimus-eluting stent implantation (4–6).
irolimus Induces Vascular Dysfunction
ndothelial-dependent and -independent vasodilator re-
ponses were significantly impaired after 7 days of sirolimus
reatment (Figs. 1A and 1B, Table 1). Reduced
ndothelium-dependent vasorelaxation has also been de-
cribed for short-time in vitro sirolimus incubation of
nd Serum Nitrite Levels
tion response relationship to acetylcholine (ACh) (A) and nitroglycerin (NTG) (B)
ced vascular nitric oxide (NO) formation after ACh stimulation (p  0.001; n 
r group). Data are the mean  SEM of n  5 (A, B), and 2 (C, D) independenton, a
centra
% redu
rats peurine aortic rings (13,14); however, reduced vascular
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Sirolimus-Induced Vascular Dysfunction June 3, 2008:2130–8mooth muscle relaxation to endothelium-independent va-
odilators was not observed in these previous studies. Our
resent findings indicate that sirolimus exposure leads to
oth endothelial and smooth muscle cell dysfunction. Be-
ause steady state arterial tissue concentrations are ap-
roached only after several days of drug exposure (26), a
ontinuous sirolimus treatment as used in the current study
eems essential to assess drug effects in the media. Also, a
ignificant 40% reduction in vascular NO bioavailability
as observed in the sirolimus group (Fig. 1C). Reduced NO
ormation also has been shown after acute in vitro sirolimus
xposure of vascular homogenates (13), whereas a slight
ncrease of NO content was reported in human microvas-
ular endothelial cells (27). However, the marked decrease
n serum nitrite (Fig. 1D), the oxidation product of NO
hose concentration correlates with NO biosynthesis
19,28), further supports our finding of reduced NO avail-
bility after sirolimus treatment. Likewise, sirolimus has
een shown to induce oxidative stress in cultured human
Figure 2 Effects of Sirolimus on Vascular Superoxide Levels
Effects of sirolimus (Sir) exposure on vascular superoxide levels as compared
to control animals (Ctr). Aortic cross-sections with DHE labeling (1 M), which
produces red fluorescence when oxidized to ethidium by superoxide. Elastic
laminae in media (m) with green autofluorescence. Data are representative of
n  3 independent experiments. a  adventitia; DHE  dihydroethidine;
e  endothelium; L-NAME  NG-nitro-L-argine methyl ester.icrovascular endothelial cells (27), whereas in anothern vitro study, no effect of sirolimus on superoxide production
as observed in human umbilical vein endothelial cells (29).
irolimus Causes Increased Vascular ROS Formation
ecause vascular NO is metabolized by the superoxide
nion, we hypothesized that continuous sirolimus exposure
ay stimulate vascular superoxide production. Indeed, we
etected a strong increase in superoxide levels that was not
estricted to the endothelium cell layer but was observed
hroughout the vascular wall (Figs. 2A and 2B). To check
or an involvement of the vascular NADPH oxidase, which
s activated by protein kinase C (PKC), vessels were exposed
o the direct PKC activator PMA. Indeed, phorbol ester-
nduced vascular ROS formation was found significantly
p-regulated in the sirolimus group (Fig. 3).
irolimus Activates NADPH
xidase-Dependent ROS Production
o further assess the involvement of the NADPH oxidase,
ortic cross-sections were pre-incubated with the NADPH
xidase inhibitor apocynin (Figs. 2E and 2F), which was
ndeed able to drastically reduce vascular superoxide pro-
uction. Cytosolic NADPH oxidase subunits p67phox and
ac1 were significantly up-regulated in sirolimus-treated
ortae; a trend toward increased expression was also seen for
47phox (Table 2). The rac1 protein was found specifically
ncreased in the membrane fraction, that is, in its active
orm (Fig. 4). Because the small GTP-binding protein rac1
s known to be activated during endothelial NADPH
xidase activation (30), our present findings are compatible
ith increased NADPH oxidase activity in response to
irolimus treatment (Fig. 4). Up-regulation of rac1 among
ther NADPH oxidase subunits has also been described for
Figure 3 Effects of Sirolimus on Phorbol
Ester-Induced Vascular ROS Formation
Time course of phorbol myristate-stimulated ROS production in aortic rings
measured by a luminol-peroxidase based assay. p  0.021; n  3 animals
per group. Ctr  control animals; ROS  reactive oxygen species;
Sir  sirolimus.
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June 3, 2008:2130–8 Sirolimus-Induced Vascular Dysfunctionhe FKBP12 binding immunosuppressant FK506 in a rat
enal transplant model (31). No significant changes were
ound for NOX1 and NOX2 protein expression, indicating
hat increased NADPH oxidase mediated ROS formation
fter sirolimus treatment is caused by stimulation of cyto-
olic NADPH oxidase subunit expression and by rac1
embrane translocation (Fig. 6) (32). Previously, we have
hown that increased NADPH oxidase-mediated superox-
de production may act as a kindling radical leading to
ffects of Sirolimus on the Expression of NADPH Oxidase Subunits
Table 2 Effects of Sirolimus on the Expression of NADPH Oxida
In Vivo
Treatment
p67phox
Hg Cyt Mem Hg
Control 1.00 0.14 0.74 0.15 0.26 0.04 1.00 0.07
Sirolimus 1.59 0.21* 1.15 0.15 0.45 0.08 1.13 0.13
ffects of sirolimus treatment on expression and membrane association of the soluble NADPH ox
p  0.039. †p  0.001. ‡p  0.005.
Cyt  cytosolic fraction; Hg  total protein homogenate; Mem  membrane fraction; NADPH 
Figure 4 Effects of Sirolimus on Membrane
Association of Soluble NADPH Oxidase Subunits
Effects of sirolimus on membrane association of the soluble NADPH oxidase
subunits p67phox, p47phox, and rac1. (A) Immunoblotting analysis of indicated
subunits in the membrane fraction with densimetric quantification and (B) origi-
nal blots. p  0.005 versus Ctr; n  5 to 7 animals per group. Cyt  cystolic
fraction; Mem  membrane fraction; NADPH  nicotinamide adenosine dinu-
cleotide phosphate; other abbreviations as in Figure 3.mNOS uncoupling, for example, in diabetes (20) and in
ngiotensin II hypertension (33).
irolimus Does Not Induce eNOS Uncoupling
he DHE-stained vessels were incubated with the eNOS
nhibitor L-NAME. NG-nitro-L-arginine methyl ester did
ot induce any changes in DHE signaling in the sirolimus
roup, whereas endothelial superoxide increased in control
ubjects (Figs. 2C and 2D). Hence, eNOS-derived NO
uenches basal levels of superoxide in control animals,
hereas uncoupled eNOS seems not to be a significant
ource of superoxide after sirolimus treatment. In addition,
NOS mRNA and protein expression was not changed by
irolimus (Table 3), as also observed for acute sirolimus
reatment (13). Importantly, DHE fluorescence was not
educed to control levels by the NADPH oxidase inhibitor
pocynin (Fig. 2F), pointing to other ROS sources being
ctivated in response to sirolimus treatment.
itochondrial ROS Contribute
o Sirolimus-Induced Oxidative Stress
he mitochondrial respiratory chain is the major source of
OS in most mammalian cells, and excess production of
itochondrial ROS has been implicated in aging and
ardiovascular diseases such as atherosclerosis, hypertension,
nd diabetes (34,35). A pronounced increase in mitochon-
rial ROS was induced by continuous sirolimus treatment
Fig. 5A), whereas short-term in vitro incubation of isolated
itochondria with sirolimus had no effect on superoxide
roduction (not shown). This effect was partially reversed by
itochondrial pre-incubation with the mitochondrial per-
eability transition pore (mPTP) blocker cyclosporine A,
he KATP channel inhibitor glibenclamide, and the complex
inhibitor rotenone (Figs. 5B and 6). Treatment with the
ATP channel opener diazoxide did not change sirolimus-
nduced mitochondrial ROS formation, but triggered
itochondrial ROS in the control group (Fig. 5B). These
ndings indicate that sirolimus treatment could lead to
ATP channel opening by increasing intracellular super-
xide, whereas direct effects of sirolimus on mitochon-
rial ion channels are not supported by our present data.
he mitochondrial respiratory chain complexes I to III
ave been identified as major sites of ROS production in
uman umbilical vein endothelial cells and human coro-
ary arteriolar endothelial cells (36,37). Opening of
ubunits
47phox rac1
Cyt Mem Hg Cyt Mem
 0.04 0.58 0.06 1.00 0.07 0.30 0.04 0.70 0.06
 0.06 0.71 0.09 1.65 0.07† 0.69 0.07† 0.96 0.03‡
ubunits p67phox, p47phox, and rac1. Data are the mean SEM, n  5 to 7 animals per group.
namide adenosine dinucleotide phosphate.se S
p
0.42
0.42
idase sPTP is known to induce the efflux of superoxide from
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Sirolimus-Induced Vascular Dysfunction June 3, 2008:2130–8he mitochondrial matrix into the cytoplasm, an effect
hat can be triggered by the opening of KATP channels,
hich itself can be induced by cytosolic ROS (38).
herefore, it is tempting to speculate that sirolimus-
nduced increases in cytosolic ROS from NADPH oxi-
ases may contribute to the opening of KATP channels
Figure 5 Effects of Sirolimus on Mitochondrial ROS Formation
Mitochondrial ROS formation after in vivo sirolimus treatment for 7 days.
(A) Increased formation of ROS in response to sirolimus as detected using
L012-derived chemiluminescence in isolated mitochondria. p  0.020; n  8
animals control, n  10 animals sirolimus. (B) Modulation of mitochondrial
ROS formation by cyclosporine A (CsA, 0.2 M), glibenclamide (Gliben., 10
M), rotenone (Roten., 5 M), and diazoxide (Diaz., 100 M). †p  0.005 for
Ctr versus Ctr/Diaz., other p values as indicated. n  5 animals per group.
Abbreviations as in Figure 3.
Effects of Sirolimus on the Expression of NOX1,
Table 3 Effects of Sirolimus on the Express
In Vivo Treatment
Relative mRNA Expressi
NOX1 NOX2
Control 1.00 0.07 1.00 0.13
Sirolimus 3.11 0.53* 0.97 0.53
Sirolimus treatment has no significant effects on indicated mRNA (ex
polymerase chain reaction and Western blotting, respectively. Data ar
eNOS endothelial nitric oxide synthase; mRNAmessenger ribonpnd subsequent ROS release from mitochondria via the
PTP (Fig. 6).
tudy Limitations
he current study can only provide limited insight into
he pathophysiological mechanisms leading to impaired
oronary endothelial function in a clinical setting after
tent implantation (4 – 6), given limitations such as the
omparability of rodent and human vasoreactivity, diver-
ent vasodilator responses in different vascular beds,
bsence of pre-existing atherosclerotic plaques, and lack
f the specific drug-release kinetics provided by
irolimus-eluting stents (15). Also, it seems conceivable
hat oral medication in CHD patients could interfere
ith sirolimus-induced vascular ROS production
19,39,40) whereas coronary inflammatory cell chemo-
axis may further increase local oxidative stress after
ngioplasty (41,42). Given the species-specific elimina-
ion and degradation half-life of sirolimus (43), compar-
sons of drug concentrations among different species must
e interpreted cautiously. Also, none of the previous
linical studies could conclusively explain the phenome-
on of endothelial dysfunction at 6 months (4,5),
hereas drug release is almost completed within 30 days.
erein, either the high tissue binding capacity and
rolonged elution of sirolimus (26) and/or the persistent
resence of the stent polymer (44) may contribute to endothe-
ial dysfunction and impaired re-endothelialization. However,
ecent clinical data identify endothelial dysfunction as early
s 2 weeks after sirolimus-eluting stent implantation (6). In
ddition, possible vascular side effects or adaptive mecha-
isms of a continuous systemic sirolimus treatment, as in
rgan transplant patients, cannot be extrapolated from the
urrent data. However, our findings clearly show sirolimus-
nduced vascular dysfunction and identify intracellular sig-
aling pathways that contribute to reduced vascular NO
vailability and increased ROS formation, and thereby
learly point to mechanisms leading to vascular side effects
f sirolimus.
ummary and Clinical Implications
ontinuous sirolimus exposure causes impaired endothelium-
ependent and -independent vascular relaxation, reduced
ascular NO formation, and increased transmural ROS
2, and eNOS
NOX1, NOX2, and eNOS
Relative Protein Expression
OS NOX1 NOX2 eNOS
0.07 1.00 0.12 1.00 0.59 1.00 0.29
0.08 0.89 0.10 0.89 0.34 0.86 0.14
OX1) and protein expression in rat aorta as determined by real-time
ean  SEM, n  5 to 7 animals per group. *p  0.003.
cid; NOX nicotinamide adenosine dinucleotide phosphate oxidase.NOX
ion of
on
eN
1.00
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ffects could very well contribute to clinically observed
ascular dysfunction after sirolimus-eluting stent implan-
ation, and their specific antagonization could help to
ptimize efficacy and safety of future pharmacological
ntirestenotic approaches.
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